TNF and neoplasm: MerTK CAR M reduces tumor burden, increases median survival time, and creates an inflammatory environment by increasing the levels of proinflammatory cytokines in serum, such as IL-β, IL-6, TNF-α, and monocyte chemotactic protein (MCP)-1 In-vivo.